Followers | 1066 |
Posts | 135765 |
Boards Moderated | 0 |
Alias Born | 08/25/2010 |
Wednesday, March 04, 2015 11:03:56 PM
See also: Equity, Equitable rights, Fraud
An equitable remedy that annuls or avoids a contract. Rescission is a remedy granted to a plaintiff in the case of fraud, innocent misrepresentation, or because of some other action on the defendant's behalf that amounts to undue influence, unconscionability, or makes the bargain questionable on some other equitable grounds. Rescission in equity operates to roll the contract back to the position the parties were in prior to contracting. This is referred to as rescission ab initio, or "from the beginning." It is to be distinguished from rescission de futuro, or "for the future." The latter terminology is unwisely used to describe the position of a plaintiff who is entitled to terminate a contract for breach. As an equitable remedy rescission is subject to a number of discretionary barriers including delay and affirmation. It is also important for the plaintiff to be able to effect restitutio in integrium. That requires both parties to be restored to their pre-contractual positions. The degree of complete restoration will vary depending on the particular underlying cause of action. In the case of fraud a court will be less particular with giving complete restoration, whereas for an innocent misrepresentation, anything less that complete restoration will bar rescission.
Everything I say is in my opinion, do your own DD and make your decision wisely! Don't spend more then you can afford to lose!
Recent BCRD News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/20/2024 10:25:46 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/14/2024 10:21:12 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 01/29/2024 03:16:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 10:00:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:12:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 07:35:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:30:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/14/2023 06:45:29 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 06/29/2023 08:13:41 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM